Profit Or Loss [Abstract]

Biotest AG - Filing #6464577

Concept	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31
Profit or loss [abstract]
Profit (loss) [abstract]
Revenue	—	7,262,000,000 EUR	—	—	—	—	—	6,846,000,000 EUR	—	—	—	—
Cost of sales	—	5,024,000,000 EUR	—	—	—	—	—	4,043,000,000 EUR	—	—	—	—
Gross profit	—	2,238,000,000 EUR	—	—	—	—	—	2,803,000,000 EUR	—	—	—	—
Other income	—	84,000,000 EUR	—	—	—	—	—	269,000,000 EUR	—	—	—	—
Administrative expenses	—	384,000,000 EUR	—	—	—	—	—	306,000,000 EUR	—	—	—	—
Other expense, by function	—	5,000,000 EUR	—	—	—	—	—	160,000,000 EUR	—	—	—	—
Profit (loss) from operating activities	—	945,000,000 EUR	—	—	—	—	—	1,435,000,000 EUR	—	—	—	—
Finance income	—	99,000,000 EUR	—	—	—	—	—	97,000,000 EUR	—	—	—	—
Finance costs	—	438,000,000 EUR	—	—	—	—	—	497,000,000 EUR	—	—	—	—
Impairment loss (impairment gain and reversal of impairment loss) determined in accordance with IFRS 9	—	79,000,000 EUR	—	—	—	—	—	1,000,000 EUR	—	—	—	—
Profit (loss) before tax	—	465,000,000 EUR	—	—	—	—	—	1,063,000,000 EUR	—	—	—	—
Tax expense (income)	—	202,000,000 EUR	—	—	—	—	—	207,000,000 EUR	—	—	—	—
Profit (loss)	– EUR	264,000,000 EUR	– EUR	– EUR	– EUR	264,000,000 EUR	– EUR	1,270,000,000 EUR	– EUR	1,270,000,000 EUR	– EUR	– EUR
Profit (loss), attributable to [abstract]
Profit (loss), attributable to owners of parent	—	264,000,000 EUR	—	—	—	—	—	1,270,000,000 EUR	—	—	—	—
Earnings per share [text block]	—	—	—	—	—	—	—	—	—	—	—	—
Earnings per share [abstract]
Earnings per share [line items]
Basic earnings per share [abstract]
Basic earnings (loss) per share	—	66.00	—	—	—	—	—	320.00	—	—	—	—
Diluted earnings per share [abstract]
Diluted earnings (loss) per share	—	66.00	—	—	—	—	—	320.00	—	—	—	—